Preliminary Results for the year ended 31 December 2022FDA CLEARANCE A MAJOR BREAKTHROUGH FOR PARSORTIX LIQUID BIOPSParsortix system substantially out-performs standard of care for ovarian cancer diagnosisProstate
ANGLE plc (AIM: AGL OTCQX: ANPCY), a world-leading liquid biopsy company, today announces audited preliminary results for the year ended 31 December 2020. · Full De Novo Submission made in September 2020 for US Food and Drug Administration (FDA) clearance of the Parsortix
® system for capturing and harvesting circulating tumour cells from metastatic breast cancer patients - FDA Administrative Review complete and Substantive Review in progress - FDA Additional Information Request (AIR) received and response planned for submission in May 2021
- patient enrolment completed after the year end - surgical procedures in progress and sample analysis in preparation - study expected to report headline results in Q4 2021